Skip to main content
L

Leapcure

Leapcure provides a platform that connects patients with clinical trials by utilizing patient advocacy and community engagement to enhance recruitment, engagement, and retention. The company addresses inefficiencies in clinical research by prioritizing patient experiences, saving over 1 million hours of research time across 42 countries.

Los Angeles, United StatesFounded 20155110K+ followers
Updated 20 months ago

Funding

$130K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Clinical trial recruitment faces challenges in engaging and retaining patients, leading to delays and increased costs for research. Traditional methods often overlook the patient experience, resulting in inefficiencies and a lack of diverse participation.

Solution

Leapcure connects patients with relevant clinical trials by prioritizing patient advocacy and community engagement. The platform focuses on making patient voices and concerns a priority for researchers, leading to more equitable and efficient research. By working directly with patient communities and advocacy groups, Leapcure enhances recruitment, engagement, and retention in clinical trials. The company facilitates the sharing of patient stories to inform and improve clinical research processes.

Target Audience

Leapcure's primary audience includes patients seeking clinical trial opportunities and clinical trial sponsors aiming to improve patient recruitment and engagement.

Features

  • Patient advocacy-focused clinical trial matching
  • Community engagement tools for patient recruitment
  • Platform for sharing patient experience stories with researchers
  • Support for clinical trials across 42 countries and in over 30 languages
  • Partnership network including health influencers, community leaders, and patient organizations
This profile is AI-generated and may contain inaccuracies.